Protara Therapeutics Future Growth
Future criteria checks 0/6
Protara Therapeutics's earnings are forecast to decline at 4.7% per annum while its annual revenue is expected to grow at 77.5% per year. EPS is expected to grow by 11% per annum.
Key information
-4.7%
Earnings growth rate
11.0%
EPS growth rate
Biotechs earnings growth | 42.4% |
Revenue growth rate | 77.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4 | -69 | -58 | N/A | 3 |
12/31/2025 | N/A | -58 | -48 | N/A | 3 |
12/31/2024 | N/A | -45 | -38 | N/A | 3 |
9/30/2024 | N/A | -42 | -35 | -35 | N/A |
6/30/2024 | N/A | -41 | -33 | -33 | N/A |
3/31/2024 | N/A | -42 | -35 | -35 | N/A |
12/31/2023 | N/A | -40 | -38 | -38 | N/A |
9/30/2023 | N/A | -69 | -34 | -34 | N/A |
6/30/2023 | N/A | -67 | -33 | -33 | N/A |
3/31/2023 | N/A | -64 | -28 | -28 | N/A |
12/31/2022 | N/A | -66 | -27 | -26 | N/A |
9/30/2022 | N/A | -37 | -28 | -28 | N/A |
6/30/2022 | N/A | -40 | -29 | -29 | N/A |
3/31/2022 | N/A | -45 | -34 | -34 | N/A |
12/31/2021 | N/A | -47 | -35 | -35 | N/A |
9/30/2021 | N/A | -46 | -35 | -34 | N/A |
6/30/2021 | N/A | -43 | -33 | -32 | N/A |
3/31/2021 | N/A | -37 | -29 | -28 | N/A |
12/31/2020 | N/A | -34 | -24 | -23 | N/A |
9/30/2020 | N/A | -28 | -18 | -18 | N/A |
6/30/2020 | N/A | -22 | -16 | -15 | N/A |
3/31/2020 | N/A | -16 | -11 | -11 | N/A |
12/31/2019 | N/A | -8 | -5 | -5 | N/A |
9/30/2019 | N/A | -7 | -5 | -5 | N/A |
12/31/2018 | N/A | -4 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1KPA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1KPA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1KPA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1KPA is forecast to have no revenue next year.
High Growth Revenue: 1KPA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1KPA's Return on Equity is forecast to be high in 3 years time